Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

摘要: Background: The aim of this study was to assess whether two-years treatment with Pirfenidone influences necroinflammation, fibrosis and steatosis, serum levels TGF-β1, IL-6, TNF-α CB1 CB2 gene expression, in patients chronic hepatitis C (CHC). Methods: Twenty-eight out 34 CHC virus infection were enrolled the received (1200 mg/day) for 24 months. Six dropped after 12 months PFD. Liver biopsies samples obtained at beginning end treatment. Modified HAI calculated. expression correlated progression alongside necroinflammation steatosis. liver transaminases measured two-months intervals. HCV genotype viral load also assessed. Quality life evaluated by SF36 questionnaires prognosis disease assessed Child-Pugh score. Wilcoxon test matched-pair signed ranks used analyze outcomes. Results: Intention treat analyses performed biochemistry clinical parameters. At treatment, grading reduced an average 3.2 points 82% (p < 0.05) Ishak’s stage decreased 2-points 67% 0.05). Steatosis 61% patients. IL-6 TGF-β1 significantly 93% 0.05), respectively, while diminished 47% ALT AST tended normalize 81% patients; mRNA increased 86% 29% Both, quality score improvements reported all Conclusions: two years benefits improves inflammation, steatosis higher number as previously shown 12-months Additionally, PFD improved TGFβ1 anti-fibrogenic receptor CB2.